These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 7909685)

  • 1. High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic and acute leukaemias.
    Betticher DC; Fey MF; von Rohr A; Tobler A; Jenzer H; Gratwohl A; Lohri A; Pugin P; Hess U; Pagani O
    Ann Oncol; 1994 Jan; 5(1):57-64. PubMed ID: 7909685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies.
    Robak T; Smolewski P; Urbanska-Rys H; Gora-Tybor J; Blonski JZ; Kasznicki M
    Leuk Lymphoma; 2004 May; 45(5):937-44. PubMed ID: 15291352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2-Chlorodeoxyadenosine treatment in non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia resistant to conventional chemotherapy: results of a multicentric experience. International Society for Chemo-Immunotherapy.
    Brugiatelli M; Holowiecka B; Dmoszynska A; Krieger O; Planinc-Peraica A; Labar B; Callea V; Morabito F; Jaksic B; Holowiecki J; Lutz D
    Ann Hematol; 1996 Aug; 73(2):79-84. PubMed ID: 8774616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fewer infections, but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low-grade non-Hodgkin's lymphoma.
    Betticher DC; von Rohr A; Ratschiller D; Schmitz SF; Egger T; Sonderegger T; Herrmann R; Kroner T; Zulian GB; Cavalli F; Fey MF; Cerny T
    J Clin Oncol; 1998 Mar; 16(3):850-8. PubMed ID: 9508165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cladribine in combination with mitoxantrone and cyclophosphamide(CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies.
    Robak T; Góra-Tybor J; Lech-Marańda E; Błoński JZ; Kasznicki M
    Eur J Haematol; 2001 Mar; 66(3):188-94. PubMed ID: 11350487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2-Chlorodeoxyadenosine (cladribine)-related eosinophilia in patients with lymphoproliferative diseases.
    Robak T; Błasińska-Morawiec M; Krykowski E; Hellmann A; Lewandowski K; Dmoszyńska A; Adamczyk-Cioch M; Kazimierczak M; Trepińska E; Dwilewicz-Trojaczek M; Kuratowska Z; Skotnicki AB; Nowak WS; Zdziarska B; Urasiński I
    Eur J Haematol; 1997 Oct; 59(4):216-20. PubMed ID: 9338619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia.
    Santana VM; Mirro J; Kearns C; Schell MJ; Crom W; Blakley RL
    J Clin Oncol; 1992 Mar; 10(3):364-70. PubMed ID: 1346800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma.
    Kuzel TM; Hurria A; Samuelson E; Tallman MS; Roenigk HH; Rademaker AW; Rosen ST
    Blood; 1996 Feb; 87(3):906-11. PubMed ID: 8562961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma.
    Robak T; Smolewski P; Cebula B; Szmigielska-Kaplon A; Chojnowski K; Blonski JZ
    Cancer; 2006 Oct; 107(7):1542-50. PubMed ID: 16948126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study.
    von Rohr A; Schmitz SF; Tichelli A; Hess U; Piguet D; Wernli M; Frickhofen N; Konwalinka G; Zulian G; Ghielmini M; Rufener B; Racine C; Fey MF; Cerny T; Betticher D; Tobler A;
    Ann Oncol; 2002 Oct; 13(10):1641-9. PubMed ID: 12377655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2-Chlorodeoxyadenosine treatment of low-grade lymphomas.
    Kay AC; Saven A; Carrera CJ; Carson DA; Thurston D; Beutler E; Piro LD
    J Clin Oncol; 1992 Mar; 10(3):371-7. PubMed ID: 1346801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2-Chlorodeoxyadenosine therapy in advanced chronic lymphocytic leukaemia.
    Delannoy A; Ferrant A; Martiat P; Montfort L; Doyen C; Sokal G; Michaux JL
    Nouv Rev Fr Hematol (1978); 1994 Aug; 36(4):311-5. PubMed ID: 7971251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High incidence of complications after 2-chloro-2'-deoxyadenosine combined with cyclophosphamide in patients with advanced lymphoproliferative malignancies.
    Van Den Neste E; Michaux L; Layios N; Costantini S; Francart J; Lambert C; Sonet A; André M; Robert A; Ferrant A
    Ann Hematol; 2004 Jun; 83(6):356-63. PubMed ID: 15024607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of a 2-hour infusion of 2-chlorodeoxyadenosine in the treatment of refractory or previously untreated Waldenström's macroglobulinemia.
    Hellmann A; Lewandowski K; Zaucha JM; Bieniaszewska M; Hałaburda K; Robak T
    Eur J Haematol; 1999 Jul; 63(1):35-41. PubMed ID: 10414453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia.
    Saven A; Lemon RH; Kosty M; Beutler E; Piro LD
    J Clin Oncol; 1995 Mar; 13(3):570-4. PubMed ID: 7884417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cladribine for untreated or early low-grade non-Hodgkin's lymphoma.
    Liliemark J; Martinsson U; Cavallin-Ståhl E; Svedmyr E; Porwit A; Strömberg M; Juliusson G
    Leuk Lymphoma; 1998 Aug; 30(5-6):573-81. PubMed ID: 9711919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cladribine in the treatment of chronic lymphocytic leukemia.
    Robak T
    Leuk Lymphoma; 2001 Feb; 40(5-6):551-64. PubMed ID: 11426528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma.
    Rummel MJ; Chow KU; Karakas T; Jäger E; Mezger J; von Grünhagen U; Schalk KP; Burkhard O; Hansmann ML; Ritzel H; Bergmann L; Hoelzer D; Mitrou PS
    Eur J Cancer; 2002 Sep; 38(13):1739-46. PubMed ID: 12175690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2-Chlorodeoxyadenosine in the treatment of relapsed/refractory chronic lymphoproliferative disorders.
    Rondelli D; Lauria F; Zinzani PL; Raspadori D; Ventura MA; Galieni P; Birtolo S; Forconi F; Algeri R; Tura S
    Eur J Haematol; 1997 Jan; 58(1):46-50. PubMed ID: 9020373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New prospects in the treatment of indolent lymphomas with purine analogues.
    Cheson BD
    Cancer J Sci Am; 1998 Jul; 4 Suppl 2():S27-36. PubMed ID: 9672772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.